Invivyd (IVVD) Cash from Financing Activities (2021 - 2025)
Invivyd (IVVD) reported Cash from Financing Activities of $157.2 million for Q4 2025, up 204025.97% on a YoY basis from N/an in Q4 2024, and up 169.54% quarter-over-quarter from $58.3 million in Q3 2025.
Invivyd (IVVD) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Invivyd has reported Cash from Financing Activities for 5 years, with the latest figure at $157.2 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 204025.97% year-over-year to $157.2 million; the trailing twelve-month figure through Dec 2025 stood at $215.6 million (up 448.24% YoY), and the FY2025 full-year result was $215.6 million, up 448.24% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $157.2 million, up from $58.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $334.8 million in Q2 2021, with the low at -$749000.0 in Q4 2021.
- Historically, Cash from Financing Activities has averaged $48.4 million across 5 years, with a median of $141000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 99.98% — and 2025, when it jumped 204025.97%.
- Invivyd's Cash from Financing Activities stood at -$749000.0 in 2021, then surged by 118.83% to $141000.0 in 2022, then changed by 0.0% to $141000.0 in 2023, then plunged by 45.39% to $77000.0 in 2024, then jumped by 204025.97% to $157.2 million in 2025.
- The last three Cash from Financing Activities figures came in at $157.2 million (Q4 2025), $58.3 million (Q3 2025), and $131000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | 157.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 157.18 Mn |
| Dec 31, 2025 | 157.18 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Jun 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Mar 31, 2024 | 39.10 Mn |
| Mar 31, 2024 | 39.10 Mn |
| Dec 31, 2023 | 141,000.00 |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Sep 30, 2023 | 92,000.00 |